Rare Disease Report
Physicians
Physicians
Patients & Caregivers

Early Use of Jakafi in Myelofibrosis Beneficial

DECEMBER 05, 2016
Srdan Verstovsek, MD, PhD



Srdan Verstovsek, MD, PhD of the MD Anderson Cancer Center in Houston Texas talked to us about the recent data he presented at the 58th Annual ASH Meeting & Exposition showing the long term efficacy of jakafi (ruxolitinib) in patients with myelofibrosis.

Reference

Verstovsek S, Gupta V, Gotlib J, et al. A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF). Presented at the 58th Annual ASH Meeting and Exposition; San Diego, CA; December 3-6, 2016. Abstract 3110.


Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.